News

StageZero Life Sciences’ Clinical Business Introduces Fourth Pillar to Cancer Offerings

Care Oncology Partners with WellnessScript to Offer Mental Health support to cancer patientsTORONTO, ON / ACCESSWIRE / November 7, 2023…

1 year ago

PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa

Shipment marks the first batch of Psychedelic molecules explicitly for the Authorized Prescriber SchemeVANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE…

1 year ago

NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System

LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced it has submitted a 510(k) premarket notification to the…

1 year ago

22nd Century Group (XXII) Expands Reduced Nicotine Content Tobacco IP with Latest Technology License

Additional Exclusive License with NCSU Further Expands Reduced Nicotine Content Plant Breeding CapabilitiesBUFFALO, N.Y., Nov. 07, 2023 (GLOBE NEWSWIRE) --…

1 year ago

Cannabix Completes Initial Electronics Testing on Contactless Alcohol Breathalyzer, Commences International Certification Plans

Cannabix has developed a contactless alcohol breathalyzer for employers and vehicles Cannabix Technologies Inc. Figure 1 Cannabix Contactless Alcohol Breathalyzer…

1 year ago

IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023

LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated…

1 year ago

Vericel to Present at the Stephens Annual Investment Conference

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine…

1 year ago

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing…

1 year ago

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and…

1 year ago

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025…

1 year ago